Open access
Open access
Powered by Google Translator Translator

Oncology – Gastrointestinal

ASTRO issues clinical guideline on external-beam radiation therapy for primary liver cancers.

19 Jan, 2022 | 08:36h | UTC

ASTRO Issues Clinical Guideline on External-Beam Radiation Therapy for Primary Liver Cancers – The ASCO Post

Original Article: External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline – Practical Radiation Oncology

 

M-A: Role of adjuvant therapy in esophageal cancer patients after neoadjuvant therapy and esophagectomy.

19 Jan, 2022 | 08:19h | UTC

Role of Adjuvant Therapy in Esophageal Cancer Patients After Neoadjuvant Therapy and Esophagectomy: A Systematic Review and Meta-analysis – Annals of Surgery (link to abstract – $ for full-text)

 

Commentary on Twitter

 

RCT: Nivolumab plus chemotherapy improved progression-free survival, but not overall survival, compared to placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer.

16 Jan, 2022 | 22:38h | UTC

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

 

Preliminary findings from a randomized trial showed promising results from dual PD-1 and HER2 blockade in HER2-positive gastric cancer.

14 Jan, 2022 | 08:03h | UTC

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer – Nature

Commentary: KEYNOTE-811: Pembrolizumab combination as a potentially transformative treatment for HER2-positive gastric cancer – Vall d’Hebron University Hospital

 

Commentary on Twitter

 

ASCO Guideline Update: Adjuvant Therapy for Stage II Colon Cancer.

13 Jan, 2022 | 08:19h | UTC

Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update – Journal of Clinical Oncology

 

Meta-analysis (mostly of observational studies): In patients undergoing pancreaticoduodenectomy, routine nasogastric decompression is associated with increased rates of delayed gastric emptying, major complications, and longer length of stay compared to no routine nasogastric decompression.

8 Jan, 2022 | 22:44h | UTC

Impact of routine nasogastric decompression versus no nasogastric decompression after pancreaticoduodenectomy on perioperative outcomes: meta-analysis – BJS Open

Related Study: Nasogastric Decompression vs No Decompression After Pancreaticoduodenectomy: The Randomized Clinical IPOD Trial – JAMA Surgery

 

Commentary on Twitter

 

Review: Immunotherapies for hepatocellular carcinoma.

14 Dec, 2021 | 08:47h | UTC

Immunotherapies for hepatocellular carcinoma – Nature Reviews Clinical Oncology (free for a limited period – if the link is paywalled, try this one)

 

Colorectal cancer incidence, mortality, tumor characteristics, and treatment before and after the introduction of the fecal immunochemical testing-based screening program in the Netherlands: a population-based study.

13 Dec, 2021 | 08:50h | UTC

Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)

 

Commentary on Twitter

 

M-A: Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma.

8 Dec, 2021 | 09:48h | UTC

Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis – JAMA Network Open

 

Commentary on Twitter

 

RCT: Cytoreductive surgery for relapsed ovarian cancer.

2 Dec, 2021 | 09:51h | UTC

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer – New England Journal of Medicine

 

Review: Current treatment and future directions in the management of anal cancer.

1 Dec, 2021 | 08:38h | UTC

Current treatment and future directions in the management of anal cancer – CA: A Cancer Journal for Clinicians

 

M-A (mostly observational studies): Comparison of gastrojejunostomy to endoscopic stenting for gastric outlet obstruction.

30 Nov, 2021 | 10:08h | UTC

Comparison of gastrojejunostomy to endoscopic stenting for gastric outlet obstruction: An updated Systematic Review and Meta‐analysis – The American Journal of Surgery

 

M-A: Treatment for gastrointestinal and pancreatic neuroendocrine tumors.

26 Nov, 2021 | 09:53h | UTC

Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis – Cochrane Library

Summary: Treatment options for neuroendocrine tumours – Cochrane Library

 

Closure of Temporary Ileostomy 2 Versus 12 Weeks After Rectal Resection for Cancer: A Word of Caution from a Prospective, Randomized Controlled Multicenter Trial.

26 Nov, 2021 | 09:42h | UTC

Closure of Temporary Ileostomy 2 Versus 12 Weeks After Rectal Resection for Cancer: A Word of Caution From a Prospective, Randomized Controlled Multicenter Trial – Diseases of the Colon & Rectum

 

Clinical practice guideline for the treatment of malignant ascites.

25 Nov, 2021 | 10:28h | UTC

Clinical practice guideline for the treatment of malignant ascites: section summary in Clinical Practice Guideline for peritoneal dissemination (2021) – International Journal of Clinical Oncology

 

Consensus Statement: U.S. Multi-Society Task Force on Colorectal Cancer now suggests average-risk CRC screening begins at age 45.

21 Nov, 2021 | 23:01h | UTC

Updates on Age to Start and Stop Colorectal Cancer Screening: Recommendations From the U.S. Multi-Society Task Force on Colorectal Cancer – Gastroenterology

News release: US Multi-Society Task Force on colorectal cancer releases updated screening recommendations - American Gastroenterological Association

Related:

State of the Art Review: Screening and prevention of colorectal cancer.

USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.

ACG Clinical Guidelines: Start colorectal cancer screening at 45

 

Long-term results of RCT: Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer.

19 Nov, 2021 | 10:15h | UTC

Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial – JAMA Oncology (free for a limited period)

Author Interview: Chemoradiotherapy Plus Induction or Consolidation Chemotherapy for Locally Advanced Rectal Cancer – JAMA Oncology

 

Commentary on Twitter

 

Nursing care for oncologic patients undergoing surgery using an enhanced recovery approach.

17 Nov, 2021 | 08:22h | UTC

Oncologic Surgical Care Using an Enhanced Recovery Approach – AACN Advanced Critical Care

News release: Enhanced Recovery Approach Changes Care for Surgical Oncology Patients – American Association of Critical-Care Nurses

Related: Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines

 

Among patients with cancer who received decompressive G-tubes for nutrition or malignant bowel obstruction, nearly half presented with stage IV disease and died within one month of placement.

12 Nov, 2021 | 09:55h | UTC

Gastrostomy Tube for Nutrition and Malignant Bowel Obstruction in Patients with Cancer – Journal of the National Comprehensive Cancer Network

Commentary: Risks and Benefits Associated With Gastrostomy Tubes for Patients With Cancer – The ASCO Post

 

RCT: One-time flexible sigmoidoscopy screening is associated with long-term reduction in colorectal cancer incidence and mortality.

10 Nov, 2021 | 07:04h | UTC

Long-Term Follow-up of the Italian Flexible Sigmoidoscopy Screening Trial – Annals of Internal Medicine

Commentaries:

Flexible sigmoidoscopy associated with long-term reduction in colorectal cancer incidence, mortality – ACP Internist

Flexible sigmoidoscopy screening associated with long-term reduction in colorectal cancer incidence and mortality – American College of Physicians

 

Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors.

9 Nov, 2021 | 01:04h | UTC

Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors – JCO Oncology Practice

 

Commentary on Twitter

 

M-A: Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer.

7 Nov, 2021 | 20:07h | UTC

Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis – EClinicalMedicine

 

Review: Clinical management of pancreatic premalignant lesions.

31 Oct, 2021 | 19:56h | UTC

Clinical Management of Pancreatic Premalignant Lesions – Gastroenterology

 

RCT: Laparoscopic vs. open distal gastrectomy for locally advanced gastric cancer.

26 Oct, 2021 | 01:40h | UTC

Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Outcomes From the CLASS-01 Randomized Clinical Trial – JAMA Surgery (free for a limited period)

 

Commentary on Twitter

 

RCT: Among patients with metastatic colorectal cancer, those randomized to systemic treatment alone had lower sixty-day mortality compared to those randomized to primary tumor resection followed by systemic treatment.

12 Oct, 2021 | 00:01h | UTC

Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment: The CAIRO4 Phase 3 Randomized Clinical Trial – JAMA Surgery (free for a limited period)

Editorial: Primary Tumor Resection and Patients With Asymptomatic Colorectal Cancer and Nonresectable Metastases: Results of Recent Randomized Trials – JAMA Surgery (free for a limited period)

Commentary: Systemic Therapy Alone Bests Surgical Tx for Metastatic CRC – BreakingMed

 

Commentary on Twitter

 

Stay Updated in Your Specialty

No spam, just news.